DermTech, Inc. announced the publication of “Economic Implications of a Non-Invasive Molecular Pathology Assay for Pigmented Skin Lesions” by John Hornberger MD and Daniel M. Siegel MD in JAMA Dermatology.
“The increasing strain on our healthcare system and the need for cutting edge technologies our patients deserve, to help detect melanoma early when the prognosis is excellent, highlight the value of the pigmented lesion assay. This test transforms the current pathway of diagnosing melanomas from one that is invasive and subjective to one that is non-invasive, objective, more accurate and significantly cheaper. Cost savings are important, but finding melanoma early is priceless,” said study author Dr. Daniel Siegel, a leading dermatologist, health economics expert and former president of the American Academy of Dermatology.
About DermTech
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit dermtech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180711005548/en/
Source: DermTech
